Patients with an established diagnosis of systemic lupus erythematosus (SLE), according to the diagnostic/classification criteria adopted by the treating clinicians and documented in the medical records.
Patients classified into either of the following groups:
SLE with established lupus nephritis (LN). SLE without evidence of lupus nephritis.
Availability of clinical and laboratory data sufficient for characterization of SLE disease status and renal involvement.
Availability of blood samples suitable for the planned molecular biomarker assessment.
You may not be if
Patients with an uncertain or undocumented diagnosis of SLE.
Patients with an unclear renal status that prevents reliable classification into the LN or non-LN group.
Patients with another active autoimmune or systemic inflammatory disease that could substantially interfere with interpretation of the investigated biomarkers.
Patients with an active infection at the time of sample collection.
Patients with a concurrent malignancy or another major condition likely to substantially affect the measured inflammatory or molecular biomarkers.
Patients with insufficient clinical information or inadequate biological samples for the planned analyses.
